Evidence map›Paper›PMID 42443410›Full record

ArticleLeukemia2026

Targeting DNA interstrand crosslinks repair with synthetic lethality in High-Grade B-Cell Lymphoma.

Stefania Fusani, Alessandro Davini, Alessandra Rossi, Saveria Mazzara, Alessio Maria Edoardo Maraglino, Anna Vanazzi, Dorotea Salemi, Stefania Orecchioni, Paolo Falvo, Giovanna Talarico and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Stefania FusaniOncohematology Division, European Institute of Oncology IRCCS, Milan, Italy.
Alessandro DaviniOncohematology Division, European Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0009-0004-8504-3604
Alessandra RossiOncohematology Division, European Institute of Oncology IRCCS, Milan, Italy.
Saveria MazzaraDepartment of Computing Sciences and Bocconi Institute for Data Science and Analytics (BIDSA), Bocconi University, Milan, Italy.
Alessio Maria Edoardo MaraglinoOncohematology Division, European Institute of Oncology IRCCS, Milan, Italy.
Anna VanazziOncohematology Division, European Institute of Oncology IRCCS, Milan, Italy.
Dorotea SalemiOncohematology Division, European Institute of Oncology IRCCS, Milan, Italy.
Stefania OrecchioniLaboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Paolo FalvoLaboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0001-5743-5046
Giovanna TalaricoLaboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Francesco BertoliniLaboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0001-5660-3255
Corrado TarellaOncohematology Division, European Institute of Oncology IRCCS, Milan, Italy.
Enrico DerenziniOncohematology Division, European Institute of Oncology IRCCS, Milan, Italy. enrico.derenzini@ieo.it.ORCID http://orcid.org/0000-0002-7154-8140

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42443410
PMCPMC13506326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.